These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 18245540

  • 1. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
    Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z.
    Clin Cancer Res; 2008 Feb 01; 14(3):788-96. PubMed ID: 18245540
    [Abstract] [Full Text] [Related]

  • 2. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
    Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z.
    Cancer Res; 2007 Dec 01; 67(23):11291-9. PubMed ID: 18056455
    [Abstract] [Full Text] [Related]

  • 3. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
    Menier C, Guillard C, Cassinat B, Carosella ED, Rouas-Freiss N.
    Leukemia; 2008 Mar 01; 22(3):578-84. PubMed ID: 18059484
    [Abstract] [Full Text] [Related]

  • 4. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
    Mathur A, Mo JR, Kraus M, O'Hare E, Sinclair P, Young J, Zhao S, Wang Y, Kopinja J, Qu X, Reilly J, Walker D, Xu L, Aleksandrowicz D, Marshall G, Scott ML, Kohl NE, Bachman E.
    Biochem Pharmacol; 2009 Aug 15; 78(4):382-9. PubMed ID: 19413997
    [Abstract] [Full Text] [Related]

  • 5. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
    Liu PC, Caulder E, Li J, Waeltz P, Margulis A, Wynn R, Becker-Pasha M, Li Y, Crowgey E, Hollis G, Haley P, Sparks RB, Combs AP, Rodgers JD, Burn TC, Vaddi K, Fridman JS.
    Clin Cancer Res; 2009 Nov 15; 15(22):6891-900. PubMed ID: 19887489
    [Abstract] [Full Text] [Related]

  • 6. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
    Ahmed KB, Warner SL, Chen A, Gourley ES, Liu X, Vankayalapati H, Nussenzveig R, Prchal JT, Bearss DJ, Parker CJ.
    Exp Hematol; 2011 Jan 15; 39(1):14-25. PubMed ID: 20934482
    [Abstract] [Full Text] [Related]

  • 7. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.
    Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y.
    Oncogene; 2007 Apr 12; 26(17):2435-44. PubMed ID: 17043651
    [Abstract] [Full Text] [Related]

  • 8. Imatinib effect on growth and signal transduction in polycythemia vera.
    Gaikwad A, Verstovsek S, Yoon D, Chang KT, Manshouri T, Nussenzveig R, Cortes J, Vainchenker W, Prchal JT.
    Exp Hematol; 2007 Jun 12; 35(6):931-8. PubMed ID: 17533047
    [Abstract] [Full Text] [Related]

  • 9. The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice.
    Abe M, Funakoshi-Tago M, Tago K, Kamishimoto J, Aizu-Yokota E, Sonoda Y, Kasahara T.
    Int Immunopharmacol; 2009 Jul 12; 9(7-8):870-7. PubMed ID: 19327411
    [Abstract] [Full Text] [Related]

  • 10. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms.
    Hu M, Xu C, Yang C, Zuo H, Chen C, Zhang D, Shi G, Wang W, Shi J, Zhang T.
    J Exp Clin Cancer Res; 2019 Feb 04; 38(1):49. PubMed ID: 30717771
    [Abstract] [Full Text] [Related]

  • 11. Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.
    Amaru Calzada A, Pedrini O, Finazzi G, Leoni F, Mascagni P, Introna M, Rambaldi A, Golay J, Associazione Italiana per la Ricerca sul Cancro-Gruppo Italiano Malattie Mieloproliferative Investigators.
    Exp Hematol; 2013 Mar 04; 41(3):253-60.e2. PubMed ID: 23111067
    [Abstract] [Full Text] [Related]

  • 12. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.
    Oku S, Takenaka K, Kuriyama T, Shide K, Kumano T, Kikushige Y, Urata S, Yamauchi T, Iwamoto C, Shimoda HK, Miyamoto T, Nagafuji K, Kishimoto J, Shimoda K, Akashi K.
    Br J Haematol; 2010 Aug 04; 150(3):334-44. PubMed ID: 20553273
    [Abstract] [Full Text] [Related]

  • 13. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
    Manshouri T, Quintás-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S.
    Cancer Sci; 2008 Jun 04; 99(6):1265-73. PubMed ID: 18482053
    [Abstract] [Full Text] [Related]

  • 14. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May 04; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 15. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
    Amaru Calzada A, Todoerti K, Donadoni L, Pellicioli A, Tuana G, Gatta R, Neri A, Finazzi G, Mantovani R, Rambaldi A, Introna M, Lombardi L, Golay J, AGIMM Investigators.
    Exp Hematol; 2012 Aug 04; 40(8):634-45.e10. PubMed ID: 22579713
    [Abstract] [Full Text] [Related]

  • 16. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
    Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A, Introna M, Barbui T, Golay J, Rambaldi A.
    Leukemia; 2008 Apr 04; 22(4):740-7. PubMed ID: 18079739
    [Abstract] [Full Text] [Related]

  • 17. The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
    Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Ruiz-Delgado GJ, Navarro-Vázquez M, González-Carrillo ML.
    Rev Invest Clin; 2006 Apr 04; 58(5):458-61. PubMed ID: 17408106
    [Abstract] [Full Text] [Related]

  • 18. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
    Dawson MA, Curry JE, Barber K, Beer PA, Graham B, Lyons JF, Richardson CJ, Scott MA, Smyth T, Squires MS, Thompson NT, Green AR, Wallis NG.
    Br J Haematol; 2010 Jul 04; 150(1):46-57. PubMed ID: 20507304
    [Abstract] [Full Text] [Related]

  • 19. The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
    Bongartz H, Hessenkemper W, Müller C, Fensky M, Fritsch J, Mandel K, Behrmann I, Haan C, Fischer T, Feller SM, Schaper F.
    Cell Signal; 2017 Jul 04; 35():37-47. PubMed ID: 28365441
    [Abstract] [Full Text] [Related]

  • 20. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
    Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A.
    Leukemia; 2009 Aug 04; 23(8):1441-5. PubMed ID: 19295546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.